SLC12A5 gene
Axonis Secures $115 Million to Develop Novel Treatment for Drug-Resistant Pain and Epilepsy
Axonis Therapeutics, drug-resistant pain, epilepsy, CNS disorders, KCC2, GABA-related inhibition, series A funding
Actionable Insights Powered by AI
Axonis Therapeutics, drug-resistant pain, epilepsy, CNS disorders, KCC2, GABA-related inhibition, series A funding